Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome

Pharmacology Research and Perspectives

Volumn 2, Issue 5, 2014, Pages

  Fujiwara, Ryoichi ^a   Itoh, Tomoo ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

CYP3A4; cytochrome P450; metabolosome; nano LC MS MS; protein protein interactions

Indexed keywords

CYTOCHROME P450 FAMILY 3; CYTOCHROME P450 FAMILY 3A4; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS;

EID: 84973280470     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.53     Document Type: Article

References (20)

1. Bernhardt R (2006). Cytochromes P450 as versatile biocatalysts. J Biotechnol 124: 128–145.
2. Davydov DR (2011). Microsomal monooxygenase as a multienzyme system: the role of P450-P450 interactions. Expert Opin Drug Metab Toxicol 7: 543–558.
3. Dutton GJ (1980). Acceptor substrates of UDP glucuronosyltransferase and their assay. Pp. 69–78in G. J. Dutton, ed. Glucuronidation of drugs and other compounds. CRC Press, Boca Raton, FL.
4. Fremont JJ, Wang RW, King CD (2005). Coimmunoprecipitation of UDP-glucuronosyltransferase isoforms and cytochrome P450 3A4. Mol Pharmacol 67: 260–262.
5. Fujiwara R, Itoh T (2014). Extensive protein-protein interactions involving UDP-glucuronosyltransferase (UGT) 2B7 in human liver microsomes. Drug Metab Pharmacokinet 29: 259–265.
6. Ishii Y, Iwanaga M, Nishimura Y, Takeda S, Ikushiro S, Nagata K, et al. (2007). Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complex. Drug Metab Pharmacokinet 22: 367–376.
7. Ishii Y, Koba H, Kinoshita K, Oizaki T, Iwamoto Y, Takeda S, et al. (2014). Alteration of the function of the UDP-glucuronosyltransferase 1A subfamily by cytochrome P450 3A4: different susceptibility for UGT isoforms and UGT1A1/7 variants. Drug Metab Dispos 42: 229–238.
8. Lang S, Erdmann F, Jung M, Wagner R, Cavalie A, Zimmermann R (2011). Sec61 complexes form ubiquitous ER Ca2+ leak channels. Channels (Austin) 5: 228–235.
9. Lewis DF (2004). 57 varieties: the human cytochromes P450. Pharmacogenomics 5: 305–318.
10. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, et al. (2005). Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15: 677–685.
11. Mori Y, Kiyonaka S, Kanai Y (2011). Transportsomes and channelsomes: are they functional units for physiological responses? Channels (Austin) 5: 387–390.
12. Nakajima M, Yokoi T (2005). Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet 20: 227–235.
13. Reed JR, Backes WL (2012). Formation of P450 · P450 complexes and their effect on P450 function. Pharmacol Ther 133: 299–310.
14. Shepherd SR, Baird SJ, Hallinan T, Burchell B (1989). An investigation of the transverse topology of bilirubin UDP-glucuronosyltransferase in rat hepatic endoplasmic reticulum. Biochem J 259: 617–620.
15. Subramanian M, Low M, Locuson CW, Tracy TS (2009). CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. Drug Metab Dispos 37: 1682–1689.
16. Subramanian M, Tam H, Zheng H, Tracy TS (2010). CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. Drug Metab Dispos 38: 1003–1009.
17. Takeda S, Ishii Y, Iwanaga M, Nurrochmad A, Ito Y, Mackenzie PI, et al. (2009). Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase 2B7: evidence for protein-protein association and possible involvement of CYP3A4 J-helix in the interaction. Mol Pharmacol 75: 956–964.
18. Taura KI, Yamada H, Hagino Y, Ishii Y, Mori MA, Oguri K (2000). Interaction between cytochrome P450 and other drug-metabolizing enzymes: evidence for an association of CYP1A1 with microsomal epoxide hydrolase and UDP-glucuronosyltransferase. Biochem Biophys Res Commun 273: 1048–1052.
19. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32: 1201–1208.
20. Zheng Y, Sun D, Sharma AK, Chen G, Amin S, Lazarus P (2007). Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 35: 1942–1948.